C-RAD POSITIONING AB
3 recall(s) on record — most severe on record: Class II.
Activity by year
- Recalls (3)
- Inspections (1)
Devices registered here (1)
- Accelerator, Linear, MedicalProduct code IYE (opens in a new tab) · Class II · Radiology · 21 CFR 892.5050
Recalls & enforcement
- Class IIOngoing2025-10-09Due to issues with the system's stereotactic radiosurgery (SRS) treatment cannot be guaranteed for all couch angles and system setups. n certain cases, the system may indicate the patient as correctly positioned at the isocenter, even when the isocenter is positioned outside of t…
- Class IIOngoing2025-04-22Software issue with scanning equipment that can results in the filed rotation not being applied correctly.
- Class IITerminated2020-08-06PC Application Software c4D not changing Site upon synchronization during the Setup workflow step
FDA inspections (1)
- VAI2018-07-19Voluntary Action Indicated · Compliance: Devices; Radiation Control and Health Safety Act; Postmarket Assurance: Devices · citations posted
Source: U.S. FDA Inspections Dashboard (opens in a new tab) (device inspection classifications, 2016–present). Data as of 2026-10-06. The dashboard profile can take several seconds to load.
Related
Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. Verify this facility record at FDA → (opens in a new tab)
Cite this record
RegWarden. “C-RAD POSITIONING AB (FEI 3006621300) — FDA facility record.” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/facility/3006621300-c-rad-positioning-ab/
Alerts for C-RAD POSITIONING AB
Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.
Want a one-page facility brief?
A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.